Radioimmunotherapy consolidation using ¹³¹I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: J Clin 2014;64:9–29.
   PubMed Web of Science ®Google Scholar
• Bauer K, Rancea M, Roloff V, et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Systemat Rev 2012;11:CD008079.
   Google Scholar
• Gill S, Carney D, Ritchie D, et al. The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Ann Oncol 2010;21:331–334.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Rai K, et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies. J Clin Oncol 2013;31:440–447.
   PubMed Web of Science ®Google Scholar
• Brown JR, Porter DL, O’Brien SM. Novel treatments for chronic lymphocytic leukemia and moving forward. Am Soc Clin Oncol 2014;34:e317–25.
   Google Scholar
• Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975–980.
   PubMed Web of Science ®Google Scholar
• Raponi S, Della Starza I, De Propris MS, et al. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. Br J Haematol 2014 (Apr 16);166:360–8.
   PubMed Web of Science ®Google Scholar
• Strati P, Keating MJ, O’Brien SM, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood 2014;123:3727–3732.
   PubMed Web of Science ®Google Scholar
• Bottcher S, Hallek M, Ritgen M, et al. The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time? Hematol/oncol Clin N Am 2013;27:267–288.
   PubMed Web of Science ®Google Scholar
• Palanca-Wessels MC, Press OW. Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas. Cancer 2010;116(4 Suppl.):1126–1133.
   PubMed Web of Science ®Google Scholar
• DeNardo GL, DeNardo SJ, Lamborn KR, et al. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother Radiopharmaceut 1998;13: 239–254.
   PubMed Web of Science ®Google Scholar
• Jain N, Wierda W, Ferrajoli A, et al. A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer 2009;115:4533–4539.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al.,International Workshop on Chronic Lymphocytic L. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Wu D, Wood BL, Fromm JR. Flow cytometry for non-Hodgkin and classical Hodgkin lymphoma. Meth Molec Biol 2013;971:27–47.
   PubMedGoogle Scholar
• Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995–1001.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Fink A, Busch R et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). American Society of Hematology annual meeting 6–9 December 2014; San Francisco, CA, USA. Blood 2014;124(Suppl):XXX
   Google Scholar
• Stehlikova O, Chovancova J, Tichy B, et al. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. Int J Lab Hematol 2014;36:165–171.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156–5164.
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Lister TA, Valente NK, et al. ¹³¹I tositumomab for patients with small lymphocytic lymphoma (SLL): overall clinical trial experience [abstract]. Blood 1999;94:88a–89a.
   Google Scholar
• Cassaday RD, Storer BE, Sorror ML, et al. Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation. Biol Blood Marrow Transplant 2015;21:281–287.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 2007;25:4285–4292.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005;105:4576–4582.
   PubMed Web of Science ®Google Scholar
• Benjamini O, Jain P, Trinh L, et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma 2015;56:1643–1650.
   PubMed Web of Science ®Google Scholar
• Keating M, O’Brien S. High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol;27(6 Suppl. 12):86–90.
   PubMed Web of Science ®Google Scholar